Ignite Creation Date:
2024-05-06 @ 12:25 PM
Last Modification Date:
2024-10-26 @ 12:58 PM
Study NCT ID:
NCT03751761
Status:
COMPLETED
Last Update Posted:
2024-02-28
First Post:
2018-11-21
Brief Title:
GC 2nd Line DurvalumabMEDI4736Tremelimumab Plus Paclitaxel Study
Sponsor:
Organization:
Asan Medical Center